Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors.

https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html